Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to ...
Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025, following strong first-half financial results that saw the company report a 6.3% rise in group net sales to €14 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results